Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 1, 2012, Pages 68-71

  Tarkiainen, E K ^a   Backman, J T ^a   Neuvonen, M ^a   Neuvonen, P J ^a   Schwab, M ^b,c   Niemi, M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; CARBOXYLESTERASE; CARBOXYLESTERASE 1; OSELTAMIVIR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CARBOXYLIC ESTER HYDROLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; GENOTYPE; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; OSELTAMIVIR; POLYMORPHISM, GENETIC; PRODRUGS;

EID: 84862593799     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.13     Document Type: Article

References (16)

1. Widmer, N., Meylan, P., Ivanyuk, A., Aouri, M., Decosterd, L.A. & Buclin, T. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin. Pharmacokinet. 49, 741-765 (2010).
2. He, G., Massarella, J. & Ward, P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37, 471-484 (1999).
3. Massarella, J.W., He, G.Z., Dorr, A., Nieforth, K., Ward, P. & Brown, A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J. Clin. Pharmacol. 40, 836-843 (2000).
4. Shi, D. et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J. Pharmacol. Exp. Ther. 319, 1477-1484 (2006).
5. Zhu, H.J. & Markowitz, J.S. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab. Dispos. 37, 264-267 (2009).
6. Satoh, T. & Hosokawa, M. Structure, function and regulation of carboxylesterases. Chem. Biol. Interact. 162, 195-211 (2006).
7. Satoh, T. & Hosokawa, M. The mammalian carboxylesterases: from molecules to functions. Annu. Rev. Pharmacol. Toxicol. 38, 257-288 (1998).
8. Markey, G.M. Carboxylesterase 1 (Ces1): from monocyte marker to major player. J. Clin. Pathol. 64, 107-109 (2011).
9. Zhu, H.J. et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am. J. Hum. Genet. 82, 1241-1248 (2008).
10. Izumi, Y., Tokuda, K., O'dell, K.A., Zorumski, C.F. & Narahashi, T. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci. Lett. 426, 54-58 (2007).
11. Davies, B.E. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J. Antimicrob. Chemother. 65 (suppl. 2), ii5-ii10 (2010).
12. Li, J., Zhang, L., Zhou, H., Stoneking, M. & Tang, K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum. Mol. Genet. 20, 528-540 (2011).
13. Pasanen, M.K., Backman, J.T., Neuvonen, P.J. & Niemi, M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 62, 409-415 (2006).
14. Keskitalo, J.E., Kurkinen, K.J., Neuvoneni, P.J. & Niemi, M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin. Pharmacol. Ther. 84, 457-461 (2008).
15. Keskitalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, P.J. &Niemi, M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 86, 197-203 (2009).
16. Laitinen, A. & Niemi, M. Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population. Basic Clin. Pharmacol. Toxicol. 108, 9-13 (2011).